The current status of COVID-19 vaccines. A scoping review

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food...

Descripción completa

Detalles Bibliográficos
Autores principales: Rueda-Fernández, Manuel, Melguizo-Rodríguez, Lucía, Costela-Ruiz, Víctor J., González-Acedo, Anabel, Ramos-Torrecillas, Javier, Illescas-Montes, Rebeca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Post-Screen (Grey)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839/
https://www.ncbi.nlm.nih.gov/pubmed/35995361
http://dx.doi.org/10.1016/j.drudis.2022.08.004
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.

Ejemplares similares